View in EDS HTML Full Text PDF Full Text

Efficacy of third-line chemotherapy following nanoliposomal irinotecan combined with fluorouracil and folinic acid as second-line treatment for unresectable pancreatic cancer.

Saved in:
Bibliographic Details
Title: Efficacy of third-line chemotherapy following nanoliposomal irinotecan combined with fluorouracil and folinic acid as second-line treatment for unresectable pancreatic cancer.
Authors: Miwa K; Multidisciplinary Treatment Cancer Center, Kurume University Hospital, Fukuoka, Japan., Kawasaki R; Division of Integrative Medical Oncology, Saiseikai Kumamoto Hospital, Kumamoto, Japan., Shimokawa M; Clinical Research Institute, National Kyushu Cancer Center, Fukuoka, Japan.; Department of Biostatistics, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan., Otsuka T; Department of Internal Medicine, Minato Medical Clinic, Fukuoka, Japan., Tanaka T; Multidisciplinary Treatment Cancer Center, Kurume University Hospital, Fukuoka, Japan., Fukahori M; Multidisciplinary Treatment Cancer Center, Kurume University Hospital, Fukuoka, Japan., Shibuki T; Department for the Promotion of Drug and Diagnostic Development, Division of Drug and Diagnostic Development Promotion, Translational Research Support Office, National Cancer Center Hospital East, Chiba, Japan.; Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, Chiba, Japan., Nakazawa J; Department of Medical Oncology, Kagoshima City Hospital, Kagoshima, Japan., Arima S; Digestive and Lifestyle Diseases, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan., Koga F; Department of Hepatobiliary and Pancreatology, Saga Medical Center Koseikan, Saga, Japan., Ueda Y; Department of Hematology and Oncology, Japanese Red Cross Kumamoto Hospital, Kumamoto, Japan., Kubotsu Y; Department of Internal Medicine, Karatsu Red Cross Hospital, Saga, Japan., Shimokawa H; Department of Hematology Oncology, Japan Community Healthcare Organization Kyushu Hospital, Fukuoka, Japan.; Department of Medical Oncology, Hamanomachi Hospital, Fukuoka, Japan., Takeshita S; Department of Gastroenterology, Japanese Red Cross Nagasaki Genbaku Hospital, Nagasaki, Japan., Nishikawa K; Department of Medical Oncology and Hematology, Oita University Faculty of Medicine, Oita, Japan., Komori A; Department of Medical Oncology and Hematology, Oita University Faculty of Medicine, Oita, Japan.; Department of Gastrointestinal Medical Oncology, National Hospital Organization Shikoku Cancer Center, Ehime, Japan., Otsu S; Department of Medical Oncology and Hematology, Oita University Faculty of Medicine, Oita, Japan., Hosokawa A; Department of Clinical Oncology, University of Miyazaki Hospital, Miyazaki, Japan., Sakai T; Department of Medical Oncology, NHO Kumamoto Medical Center, Kumamoto, Japan., Oda H; Division of Integrative Medical Oncology, Saiseikai Kumamoto Hospital, Kumamoto, Japan., Kawahira M; Department of Gastroenterology, Kagoshima Kouseiren Hospital, Kagoshima, Japan., Arita S; Department of Chemotherapy, Miyazaki Prefectural Miyazaki Hospital, Miyazaki, Japan., Honda T; Department of Gastroenterology and Hepatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan., Taguchi H; Department of Gastroenterology, Izumi General Medical Center, Kagoshima, Japan.; Department of Gastroenterology, Kagoshima City Hospital, Kagoshima, Japan., Tsuneyoshi K; Department of Gastroenterology, Izumi General Medical Center, Kagoshima, Japan., Fujita T; Department of Gastroenterology, Saiseikai Sendai Hospital, Kagoshima, Japan., Sakae T; Department of Gastroenterology, Saiseikai Sendai Hospital, Kagoshima, Japan., Kawaguchi Y; Department of Gastroenterology, Asakura Medical Association Hospital, Fukuoka, Japan., Shirakawa T; Clinical Hematology Oncology Treatment Study Group, Fukuoka, Japan.; Department of Medical Checkup Center, Eikoh Hospital, Fukuoka, Japan., Mizuta T; Department of Internal Medicine, Fujikawa Hospital, Saga, Japan., Mitsugi K; Department of Medical Oncology, Sasebo Kyosai Hospital, Nagasaki, Japan.
Source: Frontiers in oncology [Front Oncol] 2025 Jul 17; Vol. 15, pp. 1626689. Date of Electronic Publication: 2025 Jul 17 (Print Publication: 2025).
Publication Type: Journal Article
Journal Info: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101568867 Publication Model: eCollection Cited Medium: Print ISSN: 2234-943X (Print) Linking ISSN: 2234943X NLM ISO Abbreviation: Front Oncol Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 40746600
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Efficacy of third-line chemotherapy following nanoliposomal irinotecan combined with fluorouracil and folinic acid as second-line treatment for unresectable pancreatic cancer.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Miwa+K%22">Miwa K</searchLink>; Multidisciplinary Treatment Cancer Center, Kurume University Hospital, Fukuoka, Japan.<br /><searchLink fieldCode="AU" term="%22Kawasaki+R%22">Kawasaki R</searchLink>; Division of Integrative Medical Oncology, Saiseikai Kumamoto Hospital, Kumamoto, Japan.<br /><searchLink fieldCode="AU" term="%22Shimokawa+M%22">Shimokawa M</searchLink>; Clinical Research Institute, National Kyushu Cancer Center, Fukuoka, Japan.; Department of Biostatistics, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan.<br /><searchLink fieldCode="AU" term="%22Otsuka+T%22">Otsuka T</searchLink>; Department of Internal Medicine, Minato Medical Clinic, Fukuoka, Japan.<br /><searchLink fieldCode="AU" term="%22Tanaka+T%22">Tanaka T</searchLink>; Multidisciplinary Treatment Cancer Center, Kurume University Hospital, Fukuoka, Japan.<br /><searchLink fieldCode="AU" term="%22Fukahori+M%22">Fukahori M</searchLink>; Multidisciplinary Treatment Cancer Center, Kurume University Hospital, Fukuoka, Japan.<br /><searchLink fieldCode="AU" term="%22Shibuki+T%22">Shibuki T</searchLink>; Department for the Promotion of Drug and Diagnostic Development, Division of Drug and Diagnostic Development Promotion, Translational Research Support Office, National Cancer Center Hospital East, Chiba, Japan.; Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, Chiba, Japan.<br /><searchLink fieldCode="AU" term="%22Nakazawa+J%22">Nakazawa J</searchLink>; Department of Medical Oncology, Kagoshima City Hospital, Kagoshima, Japan.<br /><searchLink fieldCode="AU" term="%22Arima+S%22">Arima S</searchLink>; Digestive and Lifestyle Diseases, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan.<br /><searchLink fieldCode="AU" term="%22Koga+F%22">Koga F</searchLink>; Department of Hepatobiliary and Pancreatology, Saga Medical Center Koseikan, Saga, Japan.<br /><searchLink fieldCode="AU" term="%22Ueda+Y%22">Ueda Y</searchLink>; Department of Hematology and Oncology, Japanese Red Cross Kumamoto Hospital, Kumamoto, Japan.<br /><searchLink fieldCode="AU" term="%22Kubotsu+Y%22">Kubotsu Y</searchLink>; Department of Internal Medicine, Karatsu Red Cross Hospital, Saga, Japan.<br /><searchLink fieldCode="AU" term="%22Shimokawa+H%22">Shimokawa H</searchLink>; Department of Hematology Oncology, Japan Community Healthcare Organization Kyushu Hospital, Fukuoka, Japan.; Department of Medical Oncology, Hamanomachi Hospital, Fukuoka, Japan.<br /><searchLink fieldCode="AU" term="%22Takeshita+S%22">Takeshita S</searchLink>; Department of Gastroenterology, Japanese Red Cross Nagasaki Genbaku Hospital, Nagasaki, Japan.<br /><searchLink fieldCode="AU" term="%22Nishikawa+K%22">Nishikawa K</searchLink>; Department of Medical Oncology and Hematology, Oita University Faculty of Medicine, Oita, Japan.<br /><searchLink fieldCode="AU" term="%22Komori+A%22">Komori A</searchLink>; Department of Medical Oncology and Hematology, Oita University Faculty of Medicine, Oita, Japan.; Department of Gastrointestinal Medical Oncology, National Hospital Organization Shikoku Cancer Center, Ehime, Japan.<br /><searchLink fieldCode="AU" term="%22Otsu+S%22">Otsu S</searchLink>; Department of Medical Oncology and Hematology, Oita University Faculty of Medicine, Oita, Japan.<br /><searchLink fieldCode="AU" term="%22Hosokawa+A%22">Hosokawa A</searchLink>; Department of Clinical Oncology, University of Miyazaki Hospital, Miyazaki, Japan.<br /><searchLink fieldCode="AU" term="%22Sakai+T%22">Sakai T</searchLink>; Department of Medical Oncology, NHO Kumamoto Medical Center, Kumamoto, Japan.<br /><searchLink fieldCode="AU" term="%22Oda+H%22">Oda H</searchLink>; Division of Integrative Medical Oncology, Saiseikai Kumamoto Hospital, Kumamoto, Japan.<br /><searchLink fieldCode="AU" term="%22Kawahira+M%22">Kawahira M</searchLink>; Department of Gastroenterology, Kagoshima Kouseiren Hospital, Kagoshima, Japan.<br /><searchLink fieldCode="AU" term="%22Arita+S%22">Arita S</searchLink>; Department of Chemotherapy, Miyazaki Prefectural Miyazaki Hospital, Miyazaki, Japan.<br /><searchLink fieldCode="AU" term="%22Honda+T%22">Honda T</searchLink>; Department of Gastroenterology and Hepatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.<br /><searchLink fieldCode="AU" term="%22Taguchi+H%22">Taguchi H</searchLink>; Department of Gastroenterology, Izumi General Medical Center, Kagoshima, Japan.; Department of Gastroenterology, Kagoshima City Hospital, Kagoshima, Japan.<br /><searchLink fieldCode="AU" term="%22Tsuneyoshi+K%22">Tsuneyoshi K</searchLink>; Department of Gastroenterology, Izumi General Medical Center, Kagoshima, Japan.<br /><searchLink fieldCode="AU" term="%22Fujita+T%22">Fujita T</searchLink>; Department of Gastroenterology, Saiseikai Sendai Hospital, Kagoshima, Japan.<br /><searchLink fieldCode="AU" term="%22Sakae+T%22">Sakae T</searchLink>; Department of Gastroenterology, Saiseikai Sendai Hospital, Kagoshima, Japan.<br /><searchLink fieldCode="AU" term="%22Kawaguchi+Y%22">Kawaguchi Y</searchLink>; Department of Gastroenterology, Asakura Medical Association Hospital, Fukuoka, Japan.<br /><searchLink fieldCode="AU" term="%22Shirakawa+T%22">Shirakawa T</searchLink>; Clinical Hematology Oncology Treatment Study Group, Fukuoka, Japan.; Department of Medical Checkup Center, Eikoh Hospital, Fukuoka, Japan.<br /><searchLink fieldCode="AU" term="%22Mizuta+T%22">Mizuta T</searchLink>; Department of Internal Medicine, Fujikawa Hospital, Saga, Japan.<br /><searchLink fieldCode="AU" term="%22Mitsugi+K%22">Mitsugi K</searchLink>; Department of Medical Oncology, Sasebo Kyosai Hospital, Nagasaki, Japan.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101568867%22">Frontiers in oncology</searchLink> [Front Oncol] 2025 Jul 17; Vol. 15, pp. 1626689. <i>Date of Electronic Publication: </i>2025 Jul 17 (<i>Print Publication: </i>2025).
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Frontiers+Research+Foundation]%22">Frontiers Research Foundation] </searchLink><i>Country of Publication: </i>Switzerland <i>NLM ID: </i>101568867 <i>Publication Model: </i>eCollection <i>Cited Medium: </i>Print <i>ISSN: </i>2234-943X (Print) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%222234943X%22">2234943X </searchLink><i>NLM ISO Abbreviation: </i>Front Oncol <i>Subsets: </i>PubMed not MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=40746600
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.3389/fonc.2025.1626689
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 1626689
    Titles:
      – TitleFull: Efficacy of third-line chemotherapy following nanoliposomal irinotecan combined with fluorouracil and folinic acid as second-line treatment for unresectable pancreatic cancer.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Miwa K
      – PersonEntity:
          Name:
            NameFull: Kawasaki R
      – PersonEntity:
          Name:
            NameFull: Shimokawa M
      – PersonEntity:
          Name:
            NameFull: Otsuka T
      – PersonEntity:
          Name:
            NameFull: Tanaka T
      – PersonEntity:
          Name:
            NameFull: Fukahori M
      – PersonEntity:
          Name:
            NameFull: Shibuki T
      – PersonEntity:
          Name:
            NameFull: Nakazawa J
      – PersonEntity:
          Name:
            NameFull: Arima S
      – PersonEntity:
          Name:
            NameFull: Koga F
      – PersonEntity:
          Name:
            NameFull: Ueda Y
      – PersonEntity:
          Name:
            NameFull: Kubotsu Y
      – PersonEntity:
          Name:
            NameFull: Shimokawa H
      – PersonEntity:
          Name:
            NameFull: Takeshita S
      – PersonEntity:
          Name:
            NameFull: Nishikawa K
      – PersonEntity:
          Name:
            NameFull: Komori A
      – PersonEntity:
          Name:
            NameFull: Otsu S
      – PersonEntity:
          Name:
            NameFull: Hosokawa A
      – PersonEntity:
          Name:
            NameFull: Sakai T
      – PersonEntity:
          Name:
            NameFull: Oda H
      – PersonEntity:
          Name:
            NameFull: Kawahira M
      – PersonEntity:
          Name:
            NameFull: Arita S
      – PersonEntity:
          Name:
            NameFull: Honda T
      – PersonEntity:
          Name:
            NameFull: Taguchi H
      – PersonEntity:
          Name:
            NameFull: Tsuneyoshi K
      – PersonEntity:
          Name:
            NameFull: Fujita T
      – PersonEntity:
          Name:
            NameFull: Sakae T
      – PersonEntity:
          Name:
            NameFull: Kawaguchi Y
      – PersonEntity:
          Name:
            NameFull: Shirakawa T
      – PersonEntity:
          Name:
            NameFull: Mizuta T
      – PersonEntity:
          Name:
            NameFull: Mitsugi K
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 17
              M: 07
              Text: 2025 Jul 17
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-print
              Value: 2234-943X
          Numbering:
            – Type: volume
              Value: 15
          Titles:
            – TitleFull: Frontiers in oncology
              Type: main
ResultId 1